

IN THE CLAIMS:

Please amend the claims as follows:

1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)

17. (currently amended) An anti pneumococcal pharmaceutical composition comprising:
(a) a combination of the at least two therapeutically effective amidase anti pneumococcal lytic enzyme Pal and the muramidase anti pneumococcal lytic enzyme Cpl-1 enzymes obtained from bacteriophage, wherein Pal and Cpl-1 are present at 0.5 minimal inhibitory concentration (MIC) or less and the combination demonstrates a bacterial titer reduction of $\geq 2 \log_{10}$ greater than the single Pal or Cpl-1 agents wherein said at least two bacteriophage derived lytic enzymes are selected from the group consisting of an amidase and a muramidase; and

(b) a carrier suitable for delivery of the lytic enzymes to the site of infection, ;
~~wherein the combination of the at least two enzymes in the composition shows more than additive pneumococcal killing on a logarithmic scale and wherein the amidase is Pal and the muramidase is Cpl-1.~~

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (currently amended) An anti-microbial composition for sanitizing or decontaminating porous or non-porous surfaces suspected of containing *Streptococcus pneumoniae* comprising a combination of the amidase anti pneumococcal lytic enzyme Pal and the muramidase anti pneumococcal lytic enzyme Cpl-1 obtained from bacteriophage, wherein Pal and Cpl-1 are present at 0.5 minimal inhibitory concentration (MIC) or less and the combination demonstrates a bacterial titer reduction of $\geq 2 \log_{10}$ greater than the single Pal or Cpl-1 agents. ~~at least two anti-microbial lytic enzymes obtained from bacteriophage, wherein said at least two bacteriophage derived lytic enzymes are selected from the group consisting of an amidase and a muramidase, wherein the combination of the at least two enzymes in the composition shows more than additive *Streptococcus pneumoniae* killing on a logarithmic scale, and wherein the amidase is Pal and the muramidase is Cpl-1.~~

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. (new) An anti pneumococcal pharmaceutical composition comprising:

- (a) a combination of the amidase anti pneumococcal lytic enzyme Pal and the muramidase anti pneumococcal lytic enzyme Cpl-1 obtained from bacteriophage, comprising a mixture of Pal and Cpl-1 at a concentration of 0.5 U/ml wherein the killing efficacy of the mixture is increased by greater than 1 log₁₀ compared to 1 U/ml of Pal or Cpl-1 alone ; and
- (b) a carrier suitable for delivery of the lytic enzymes to the site of infection.

31. (new) An anti-microbial composition for sanitizing or decontaminating porous or non-porous surfaces suspected of containing *Streptococcus pneumoniae* comprising a combination of the amidase anti pneumococcal lytic enzyme Pal and the muramidase anti pneumococcal lytic enzyme Cpl-1 obtained from bacteriophage, comprising a mixture of Pal and Cpl-1 at a concentration of 0.5 U/ml wherein the killing efficacy of the mixture is increased by greater than 1 log₁₀ compared to 1 U/ml of Pal or Cpl-1 alone.